# Li Sun

> Li Sun is the founder and CEO of Shennon Biotechnologies, a San Francisco single-cell immunotherapy company that profiles millions of immune cells in hours to pinpoint the rare T cells and antibody targets that fight cancer. A physicist by training (PhD from Harvard's Weitz lab, M.Eng from MIT), she spent five years as a deep-tech venture investor at Bessemer and Foundation Capital before building the platform herself. Shennon emerged from stealth in March 2023 with a $13M seed round led by DCVC.

- **Role:** Founder & CEO at Shennon Biotechnologies
- **Organizations:** Shennon Biotechnologies, Foundation Capital, Bessemer Venture Partners
- **Education:** PhD, Applied Physics (single-cell analysis, Weitz Lab), Harvard University, M.Eng, Materials Science, Massachusetts Institute of Technology (MIT), B.Eng, Electrical Engineering (minor in Business), Nanyang Technological University, Singapore
- **Known for:** Founded and leads Shennon Biotechnologies, raising a $13M oversubscribed seed round led by DCVC (March 2023), Developed a proprietary single-cell platform that functionally profiles millions of immune cells in a few hours, Cut immunotherapy target identification from weeks or months down to roughly a day

## Career timeline

- **—** — B.Eng in Electrical Engineering at Nanyang Technological University, Singapore
- **—** — M.Eng in Materials Science at MIT, studying under Yet-Ming Chiang
- **—** — PhD in Applied Physics at Harvard in David Weitz's lab, focused on single-cell analysis
- **—** — Begins venture career at Bessemer Venture Partners
- **—** — Partner at Foundation Capital, backing deep-tech startups (~5 years in VC total)
- **2021** — Founds Shennon Biotechnologies in January 2021
- **2023** — Shennon Bio exits stealth with $13M seed round led by DCVC

## Achievements

- Founded and leads Shennon Biotechnologies, raising a $13M oversubscribed seed round led by DCVC (March 2023)
- Developed a proprietary single-cell platform that functionally profiles millions of immune cells in a few hours
- Cut immunotherapy target identification from weeks or months down to roughly a day
- Built an interdisciplinary career spanning electrical engineering, materials science, applied physics, and venture capital

## Latest updates

- **2023-03** — Shennon Biotechnologies emerged from stealth with a $13M seed round led by DCVC, with Foundation Capital, AV8 and angels participating.

## Links

- Website: https://shennonbio.com
- LinkedIn: http://www.linkedin.com/in/li-sun-phd-6040271b

---

Profile page: https://yespress.io/li-sun
Published by YesPress — https://yespress.io
Last updated: 2026-06-27